Roche – Recovering Post Covid

Roche – Recovering Post Covid

Key Indicators
Index / Fund / Rate
Start of Year
Last Week
This Week
% Change YTD
Index / Fund / Rate
Lunar BCI WW Flexible Fund
Start of Year
141.43
Last Week
175.19
This Week
170.40
% Change YTD
20.48% Lunar Capital increasesymbol
Index / Fund / Rate
JSE ALSI
Start of Year
73 049
Last Week
70 198
This Week
69 452Lunar Capital stocktake arrow down
% Change YTD
-4.92% Lunar Capital stocktake arrow down
Index / Fund / Rate
NASDAQ Composite
Start of Year
10 467
Last Week
12 984
This Week
12 643 Lunar Capital stocktake arrow down
% Change YTD
20.80% Lunar Capital increasesymbol
Index / Fund / Rate
S&P 500
Start of Year
3 840
Last Week
4 224
This Week
4 117 Lunar Capital stocktake arrow down
% Change YTD
7.21% Lunar Capital increasesymbol
Index / Fund / Rate
Prime Lending Rate
Start of Year
10.50%
Last Week
11.75%
This Week
11.75%
% Change YTD
11.90% Lunar Capital increasesymbol
Index / Fund / Rate
USD/ZAR
Start of Year
16.98
Last Week
19.03
This Week
18.84 Lunar Capital stocktake arrow down
% Change YTD
10.95% Lunar Capital increasesymbol
Index / Fund / Rate
EUR/ZAR
Start of Year
18.44
Last Week
20.15
This Week
19.91 Lunar Capital stocktake arrow down
% Change YTD
7.97% Lunar Capital increasesymbol
Index / Fund / Rate
Brent Crude ($'barrel)
Start of Year
85.95
Last Week
92.16
This Week
90.01 Lunar Capital stocktake arrow down
% Change YTD
4.72%Lunar Capital increasesymbol
Source: Iress

Roche is a Swiss-based biotechnology company, specialising in diagnostics and pharmaceuticals.

In diagnostics, Roche has solutions for diagnosis kits for cardiometabolic, diabetes, cancer, and other diseases. Diagnosing diseases early or before they occur in susceptible people, can improve treatments choices, treatment outcomes, reduce suffering, and increase lifespans in patients.

In pharmaceuticals, Roche has treatments for haematology (blood diseases), oncology (cancer), ophthalmology (eye diseases), respiratory, and women’s diseases, amongst others.  

In summary, for the comparative 9 months to end September; Roche revenues were down 6% to ƒ44.1bn (Swiss francs), with Pharmaceuticals up by 1% and Diagnostics down by 25%; in 2023 versus 2022. The main reasons for the decline and low growth in revenues is due to almost zero demand for Covid-19 related diagnostic kits and treatments.

Encouragingly, the uptake of new medicines and diagnostics showed strong growth in both the divisions. Roche also have launches of several products in the fourth quarter and into next year.

  • Vabysmo, a treatment for specific conditions leading to a loss or deterioration of vision was launched in 2022 and is expected to become a blockbuster drug, with sales exceeding ƒ2bn in 2023.
  • Polivy, launched in 2019, and used in the treatment of lymphoma (cancer) has also shown significant in sales growth in 2023.
  • Roche’s Elecsys IL-6 is used in diagnosing sepsis in neonates (new borns) allowing early treatment that can prevent deaths in approximately 84% of cases.

Roche has invested in technology and use AI/ML (Artificial Intelligence/Machine Learning) tools in several areas of their business, including in research and development, clinical development, manufacturing, and commercialisation.  

Biotechnology businesses are subject to strict regulations and are required to get approvals from every country’s regulatory authority to be able to sell their products in those countries. Work in research and development for specific mdeicines can take many years and there is no guarantee of success.

Roche is held by Lunar Capital’s Offshore Portfolio clients and in the Lunar BCI Worldwide Flexible Fund.

Click here to access your account to view statements, obtain tax certificates, add or make changes to your investments.

Our email address is: [email protected]

Disclosures
Lunar Capital (Pty) Ltd is a registered Financial Services Provider. FSP (46567)
Read our full Disclosure statement: https://lunarcapital.co.za/disclosures/
Our Privacy Notice: https://lunarcapital.co.za/privacy-policy/
The Lunar BCI Worldwide Flexible Fund Fact Sheet  can be read here.
This stocktake is prepared for the clients of Lunar Capital (Pty) Ltd. This stocktake does not constitute financial advice and is generated for information purposes only.

Share article

Latest Posts

JP Morgan and the Fortress Balance Sheet
JP Morgan and the Fortress Balance Sheet
What stressors does JP Morgan see in the economy and how are they positioned.
Balancing the Scale
Balancing the Scale
What are some of the challenges and opportunities companies face when they are already large
Lunar Capital Quarterly Investment & Performance Review - 31 December 2023
Lunar Capital Quarterly Investment & Performance Review – 31 March 2024
Sabir provides an update of the Funds' Performance and Strategy of Lunar Capital as of end March 2024.

Lunar Capital
on Eastwave Radio

Every Wednesday, at 07h45, Sabir chats with Nazia from Eastwave Radio (92.2 fm, live stream on
www.eastwave.co.za) on investing and the markets.

eastwave-radio
Scroll to Top